Bortezomib and heart failure: case‐report and review of the French Pharmacovigilance database
Fundamental and Clinical Pharmacology2013Vol. 28(3), pp. 349–352
Citations Over TimeTop 10% of 2013 papers
Benjamin Honton, Fabien Despas, Nicolas Dumonteil, Caroline Rouvellat, Murielle Roussel, Didier Carrié, Michel Galinier, Jean Louis Montastruc, Atul Pathak
Abstract
Bortezomib is a proteasome inhibitor commonly indicated for the treatment of multiple myeloma and non Hodgkin lymphoma. Cardiac adverse drug reactions of this drug are not clearly established. We report case where direct involvement of bortezomib in the occurrence of heart failure is strongly suspected and 22 other cases spontaneously reported to the French Pharmacovigilance System. This report should increase cardiologist awareness about the risk of heart failure related to this drug. Moreover, these cases underline the need for a systematic cardiac screening in patients exposed to bortezomib.
Related Papers
- → Proteasome Inhibitors in Treatment of Multiple Myeloma(2013)3 cited
- Effect of Bortezomib on serum cystatin-C in multiple myeloma(2011)
- → Bortezomib:a proteasome inhibitor in the treatment of multiple myeloma(2008)
- → Mechanism of resistance to proteasome inhibitor bortezomib in multiple myeloma(2016)
- → Mechanisms of proteasome inhibitor bortezomib on the therapy of multiple myeloma(2011)